Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00990314 · ClinicalTrials.gov registry record · Phase 2
Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients
A Phase 2 study, sponsored by Lung Biotechnology PBC.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00990314 is a Phase 2 study that has completed, run by Lung Biotechnology PBC. The registered enrollment target is 31 participants.
The verdict
NCT00990314, a Phase 2 study, has completed, sponsored by Lung Biotechnology PBC.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is an open-label study for patients who participated in the BPS-MR-PAH-203 study and have volunteered to continue treatment for PAH with Beraprost Sodium Modified Release (BPS-MR) tablets.
Interventions
- DRUG Beraprost Sodium Modified Release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2009-11-30 |
| Est. Completion | 2013-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00990314
The ClinicalTrials.gov registry entry for NCT00990314 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lung Biotechnology PBC, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Beraprost Sodium Modified Release is the first listed.
NCT00990314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00990314 about?
NCT00990314 is a clinical study titled "Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients". This is an open-label study for patients who participated in the BPS-MR-PAH-203 study and have volunteered to continue treatment for PAH with Beraprost Sodium Modified Release (BPS-MR) tablets.
What is the current status of trial NCT00990314?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2009-11-30. Estimated completion is 2013-11-30.
What interventions are being tested in trial NCT00990314?
The interventions under investigation include: Beraprost Sodium Modified Release (DRUG).
Who is sponsoring clinical trial NCT00990314?
This trial is sponsored by Lung Biotechnology PBC, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.